Academic Radiology
Volume 14, Issue 8 , Pages 945-950 , August 2007

Detection of Ductal Carcinoma in Situ with Mammography, Breast Specific Gamma Imaging, and Magnetic Resonance Imaging: A Comparative Study

  • Rachel F. Brem, MD

      Affiliations

    • Breast Imaging and Intervention, The George Washington University, 2150 Pennsylvania Avenue NW, Washington, DC 20037
    • Corresponding Author InformationAddress correspondence to: R.F.B.
    • ,
  • Michael Fishman

      Affiliations

    • Department of Radiology, The George Washington University, 2150 Pennsylvania Avenue NW, Washington, DC 20037.
    • ,
  • Jocelyn A. Rapelyea, MD

      Affiliations

    • Breast Imaging and Intervention, The George Washington University, 2150 Pennsylvania Avenue NW, Washington, DC 20037

Received 15 February 2007 ,Accepted 8 April 2007.

References 

  1. Jemal A, Murray T, Ward E, et al. Cancer statistics 2005. CA Cancer J Clin. 2005;55:10–30
  2. Burstein HJ, Polyak K, Wong JS, et al. Ductal carcinoma in situ of the breast. N Engl J Med. 2004;350:1430–1441
  3. Bluemke DA, Gatsonis CA, Chen MH, et al. Magnetic resonance imaging of the breast prior to biopsy. JAMA. 2004;22:2735–2742
  4. Hwang ES, Kinkel K, Esserman LJ, et al. Magnetic resonance imaging in patients diagnosed with ductal carcinoma-in-situ: value in the diagnosis of residual disease, occult invasion, and multicentricity. Ann Surg Oncol. 2003;10:381–388
  5. Orel SG, Mendonca MH, Reynolds C, et al. MR imaging of ductal carcinoma in situ. Radiology. 1997;202:413–420
  6. Taillefer R. Clinical applications of 99mTc-sestamibi scintimammography. Semin Nucl Med. 2005;35:100–115
  7. Schillaci O, Buscombe JR. Breast scintigraphy today: indications and limitations. Eur J Nucl Med Mol Imaging. 2004;31(Suppl 1):S35–S45
  8. Khalkhali I, Cutrone JA, Mena IG, et al. Scintimammography: the complementary role of Tc99m sestamibi prone breast imaging for the diagnosis of breast carcinoma. Radiology. 1995;196:421–426
  9. Khalkhali I, Villanueva-Meyer J, Edell SL, et al. Diagnostic accuracy of 99m Tc-Sestamibi breast imaging: multicenter trial results. J Nucl Med. 2000;41:1973–1979
  10. Papantoniou V, Tsiouris S, Mainta E, et al. Imaging in situ breast carcinoma (with or without an invasive component) with technetium-99m 20methoxy isobutyl isonitrile scintimammography. Breast Cancer Res. 2005;7:R33–R45
  11. Ikeda DM, Birdwell RL, Daniel BL. Potential role of magnetic resonance imaging and other modalities in ductal carcinoma in situ detection. MRI Clin N Am. 2001;9:345–356

1 Bristol-Myers Squibb (Billerica, MA) provided grant support for the study and offered the radiotracer as an in-kind donation. No authors are employed by Bristol-Myers Squibb or Dilon Technologies. R.F.B. has stock options in Dilon Technologies and recently joined the Board of Managers and has been on the speaker’s bureau for Bristol-Myers Squibb (previously DuPont Pharmaceuticals). No other authors have any other relationship with Bristol-Myers Squibb or Dilon Technologies. The data reported in this study, as well as the submission of this manuscript, always remained in sole possession of the authors.

PII: S1076-6332(07)00194-8

doi: 10.1016/j.acra.2007.04.004

Academic Radiology
Volume 14, Issue 8 , Pages 945-950 , August 2007

Article Tools

* Image Usage & Resolution